[Didanosine].
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D002648:Child; D016049:Didanosine / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D004066:Digestive System Diseases / Q000139:chemically induced; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D010195:Pancreatitis / Q000139:chemically induced / Q000453:epidemiology; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011247:Pregnancy; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use
D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D016049:Didanosine
Didanosina.